p.31 抽出テキスト

Arnett et al 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

September 10, 2019 Circulation. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678 e626

CLINICAL STATEMENTS AND GUIDELINES psychological specialists and generalist clinicians on glycaemic control and on psychological status. Patient Educ Couns. 2009;75:25–36. S2.1-47.	 Bolen SD, Chandar A, Falck-Ytter C, et al. Effectiveness and safety

of patient activation interventions for adults with type 2 diabetes: systematic review, meta-analysis, and meta-regression. J Gen Intern Med. 2014;29:1166–76. S2.1-48.	 Gonzalez JS, Tanenbaum ML, Commissariat PV. Psychosocial factors in medication adherence and diabetes self-management: Implications for research and practice. Am Psychol. 2016;71:539–51. S2.1-49.	 Javaheri S, Redline S. Insomnia and risk of cardiovascular disease. Chest. 2017;152:435–44. S2.1-50.	 Samuel LJ, Dennison Himmelfarb CR, Szklo M, et al. Social engagement and chronic disease risk behaviors: the Multi-Ethnic Study of Atherosclerosis. Prev Med. 2015;71:61–6. S2.1-51.	 Verbiest M, Brakema E, van der Kleij R, et al. National guidelines for

smoking cessation in primary care: a literature review and evidence analysis. NPJ Prim Care Respir Med. 2017;27:2.

2.2 Assessment of Cardiovascular Risk

S2.2-1. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49–73. S2.2-2. American College of Cardiology, American Heart Association. ASCVD Risk Estimator. Available at: https://tools.acc.org/ldl/ascvd_ risk_estimator/index.html#!/calulate/estimator. Accessed September 21, 2018. S2.2-3. Ference BA, Graham I, Tokgozoglu L, et al. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72:1141–56. S2.2-4. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–1143. S2.2-5. Patel J, Al Rifai M, Scheuner MT, et al. Basic vs more complex definitions of family history in the prediction of coronary heart disease: the Multi-Ethnic Study of Atherosclerosis. Mayo Clin Proc. 2018;93:1213–23. S2.2-6. del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737–45. S2.2-7. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408–15. S2.2-8. Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10:e003497. S2.2-9. Tanz LJ, Stuart JJ, Williams PL, et al. Preterm delivery and maternal cardiovascular disease in young and middle-aged adult women. Circulation. 2017;135:578–89. S2.2-10.	 Wellons M, Ouyang P, Schreiner PJ, et al. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause. 2012;19:1081–7. S2.2-11.	 Uddin SMI, Mirbolouk M, Dardari Z, et al. Erectile dysfunction as an independent predictor of future cardiovascular events. Circulation. 2018;138:540–2. S2.2-12.	 Triant VA, Perez J, Regan S, et al. Cardiovascular risk prediction functions underestimate risk in HIV infection. Circulation. 2018;137:2203–14. S2.2-13.	 Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart Association. Circulation. 2018;138:e1–34. S2.2-14.	 Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207. S2.2-15.	 DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibra-

tion and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162: 266–75. S2.2-16.	 Mahabadi AA, Möhlenkamp S, Lehmann N, et al. CAC score

improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. JACC Cardiovasc Imaging. 2017;10:143–53. S2.2-17.	 Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA). Eur Heart J. 2018;39:2401–8. S2.2-18.	 McClelland RL, Jorgensen NW, Budoff M, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study). J Am Coll Cardiol. 2015;66:1643–53. S2.2-19.	 Kavousi M, Desai CS, Ayers C, et al. Prevalence and prognostic implications of coronary artery calcification in low-risk women: a metaanalysis. JAMA. 2016;316:2126–34. S2.2-20.	 Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391–9. S2.2-21.	 Mortensen MB, Fuster V, Muntendam P, et al. A simple diseaseguided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage Study. J Am Coll Cardiol. 2016;68:881–91. S2.2-22.	 Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2016;133:849–58. S2.2-23.	 Patel J, Al Rifai M, Blaha MJ, et al. Coronary artery calcium improves risk assessment in adults with a family history of premature coronary heart disease: results from the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging. 2015;8:e003186. S2.2-24.	 Pursnani A, Massaro JM, D’Agostino RB Sr, et al. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA. 2015;314:134–41. S2.2-25.	 Valenti V, Ó Hartaigh B, Heo R, et al. A 15-year warranty period for asymptomatic individuals without coronary artery calcium: a prospective follow-up of 9 715 individuals. JACC Cardiovasc Imaging. 2015;8:900–9. S2.2-26.	 Yano Y, O’Donnell CJ, Kuller L, et al. Association of coronary artery calcium score vs age with cardiovascular risk in older adults: an analysis of pooled population-based studies. JAMA Cardiol. 2017;2:986–94. S2.2-27.	 Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol. 2016;67:139–47. S2.2-28.	 Multi-Ethnic Study of Atherosclerosis. MESA 10-Year CHD Risk with Coronary Artery Calcification. Available at: https://www. mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx. Accessed September 21, 2018. S2.2-29.	 Astronaut Cardiovascular Health and Risk Modification (Astro- CHARM). 10-Year ASCVD Risk Calculator with Coronary Artery Calcium. Available at: http://astrocharm.org/calculator-working. Accessed September 21, 2018. S2.2-30.	 Gupta A, Lau E, Varshney R, et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2017;10:833–42. S2.2-31.	 Shah RV, Spahillari A, Mwasongwe S, et al. Subclinical atherosclerosis, statin eligibility, and outcomes in African American individuals: the Jackson Heart Study. JAMA Cardiol. 2017;2:644–52. S2.2-32.	 Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791–8. S2.2-33.	 Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366:321–9. S2.2-34.	 Wilkins JT, Ning H, Berry J, et al. Lifetime risk and years lived free of total cardiovascular disease. JAMA. 2012;308:1795–801. S2.2-35.	 Pencina MJ, D’Agostino RB Sr, Larson MG, et al. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:3078–84. S2.2-36.	 Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA

guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American

Downloaded from http://ahajournals.org by on October 7, 2026